Delirium at the End of Life

被引：16

作者：

Agar, Meera ^{[1
]}

Bush, Shirley H. ^{[2
,3
,4
,5
]}

机构：

[1] Univ Technol Sydney, Fac Hlth, IMPACCT Improving Palliat Aged & Chron Care Clin, Bldg 10,Level 3,235 Jones St, Ultimo, NSW 2007, Australia

[2] Ottawa Hosp, Gen Campus,501 Smyth Rd,Box 206, Ottawa, ON K1H 8L6, Canada

[3] Bruyere Res Inst, 85 Primrose Ave, Ottawa, ON K1R 6M1, Canada

[4] Ottawa Hosp, Res Inst, 053 Carling Ave, Ottawa, ON K1Y 4E9, Canada

[5] Ottawa Hosp, Bruyere Continuing Care, Palliat Care, 43 Bruyere St, Ottawa, ON K1N 5C8, Canada

来源：

MEDICAL CLINICS OF NORTH AMERICA | 2020年 / 104卷 / 03期

关键词：

Delirium; Delirium pathophysiology; Delirium screening; Delirium prevention; Antipsychotics; Benzodiazepines; Palliative care; End of life; PALLIATIVE CARE; SUBSYNDROMAL DELIRIUM; ADVANCED CANCER; TERMINALLY-ILL; DEMENTIA; PLACEBO; HALOPERIDOL; VALIDATION; PREDICTORS; EFFICACY;

D O I：

10.1016/j.mcna.2020.01.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Delirium is a prevalent acute neurocognitive condition in patients with progressive life-limiting illness. Delirium remains underdetected; a systematic approach to screening is essential. Delirium at the end of life requires a comprehensive assessment. Consider the potential for reversibility, illness trajectory, patient preference, and goals of care before proceeding with investigations and interventions. Management should be interdisciplinary, and nonpharmacologic therapy is fundamental. For patients with refractory and severe agitation or perceptual disturbance, judicious use of medication may also be required. Carers and family should be seen as partners in care and be involved in shared decision making about care.

引用

页码：491 / +

页数：12